Skip to main content
Clinical Trials/NL-OMON52903
NL-OMON52903
Recruiting
Phase 2

[18F]PEG-Folate PET-CT imaging for monitoring of therapy response in Rheumatoid Arthritis patients - Monitoring of therapy response with PET-CT imaging in RA

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients must be at least 30 years of age
  • Diagnosis of rheumatoid arthritis according to the 1987 revised criteria of
  • the American Rheumatism Association (ARA)13 and/or the 2010 ACR/EULAR
  • Rheumatoid Arthritis classification criteria.
  • Patients with clinically active disease as assessed by a physician; with
  • arthritis in at least one synovial biopsy accessible joint and have a clinical
  • indication to start or restart (if stopped \>12 weeks) with anti\-TNF (either
  • Infliximab, Etanercept, Adalimumab or Certolizumab).
  • Prior treatment with one anti\-TNF agent (Adalimumab, Certolizumab,
  • Etanercept, Golimumab or Infliximab) is permitted, but may not be a primary

Exclusion Criteria

  • Use of intramuscular or intravenous corticosteroids within 4 weeks prior to
  • Patients who received methotrexate and folic acid less than 7 days before
  • tracer injection.
  • Treatment with any investigational drug within the previous 3 months
  • Known pregnancy or breast feeding
  • Research related radiation exposure (cumulative \>\=5 mSv) in the year before

Outcomes

Primary Outcomes

Not specified

Similar Trials